170 related articles for article (PubMed ID: 20624030)
1. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Brown JR
Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Chen CI
Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
4. Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Spina F; Rezzonico F; Farina L; Corradini P
Eur J Haematol; 2013 Apr; 90(4):340-4. PubMed ID: 23281656
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Molica S
Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Gentile M; Recchia AG; Vigna E; Mazzone C; Lucia E; Gigliotti V; Bossio S; Madeo A; Morabito L; Servillo P; Franzese S; Caruso N; De Stefano L; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Feb; 20(2):273-86. PubMed ID: 21214505
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
8. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A; Miller KC; Musial L; Lawrence D; Padmanabhan S; Takeshita K; Porter CW; Goodrich DW; Bernstein ZP; Wallace P; Spaner D; Mohr A; Byrne C; Hernandez-Ilizaliturri F; Chrystal C; Starostik P; Czuczman MS
J Clin Oncol; 2006 Dec; 24(34):5343-9. PubMed ID: 17088571
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
11. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
13. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
[TBL] [Abstract][Full Text] [Related]
14. [Application of lenalidomide in chronic lymphocytic leukemia].
Lei W; Zhou KS; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
[TBL] [Abstract][Full Text] [Related]
15. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
Lee BN; Gao H; Cohen EN; Badoux X; Wierda WG; Estrov Z; Faderl SH; Keating MJ; Ferrajoli A; Reuben JM
Cancer; 2011 Sep; 117(17):3999-4008. PubMed ID: 21858802
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
17. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia.
Moutouh-de Parseval LA; Weiss L; DeLap RJ; Knight RD; Zeldis JB
J Clin Oncol; 2007 Nov; 25(31):5047. PubMed ID: 17971612
[No Abstract] [Full Text] [Related]
18. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Arumainathan A; Kalakonda N; Pettitt AR
Eur J Haematol; 2011 Oct; 87(4):372-5. PubMed ID: 21679253
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.
Riches JC; Gribben JG
Curr Cancer Drug Targets; 2016; 16(8):689-700. PubMed ID: 27055579
[TBL] [Abstract][Full Text] [Related]
20. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA; Wang DS; Knight RD; Ruppert AS; Lehman A; Jarjoura D; Chen CS; Byrd JC
J Clin Oncol; 2008 May; 26(15):2519-25. PubMed ID: 18427150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
